Blood Pump Surface Modification with Fluorinated Oligomers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing blood pumps face challenges in minimizing stagnant blood flow regions to prevent thrombosis, as they often have surfaces with high coefficients of friction, thrombogenicity, and biofouling.
Innovation Solution
The blood pump incorporates surfaces modified with fluorinated end groups and/or silicone end groups of oligomers or copolymers, which reduce friction, thrombogenicity, and biofouling, enhancing blood flow dynamics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional surfaces are used in the blood flow section, then the device structure is simple, but the coefficient of friction is high causing stagnant blood flow and thrombosis
Solution Approach 1:
The patent applies parameter changes by modifying the surface chemical composition through fluorinated end groups and silicone end groups of oligomers or copolymers. This changes the surface energy and wettability parameters, reducing the coefficient of friction and preventing thrombosis without altering the bulk mechanical properties of the blood flow section
Solution Approach 2:
The patent uses composite materials by combining fluorinated oligomers or copolymers with silicone end groups on the blood flow section surface. This creates a composite surface structure that leverages the low friction properties of fluorinated compounds and the biocompatibility of silicone to minimize thrombogenicity
2Reliability
If conventional surfaces are used in the blood flow section, then the manufacturing process is simple, but thrombogenicity is high increasing thrombosis risk
Solution Approach 1:
The patent applies preliminary action by pre-synthesizing fluorinated oligomers or copolymers with silicone end groups before applying them to the blood flow section. This preliminary preparation of the surface-modifying material simplifies the overall manufacturing process by separating the material synthesis step from the device assembly step
Solution Approach 2:
The fluorinated oligomers or copolymers with silicone end groups serve as an intermediary substance between the blood flow section surface and the blood. This intermediary layer reduces direct interaction between blood components and the base material, lowering thrombogenicity while maintaining manufacturing simplicity
3Reliability
If conventional surfaces are used in the blood flow section, then the device structure is simple, but biofouling is high reducing pump performance
Solution Approach 1:
The patent changes the surface energy parameters by introducing fluorinated end groups and silicone end groups, which create a low-energy surface that resists protein adsorption and cell adhesion. This parameter change effectively reduces biofouling tendency without requiring complex structural modifications
Solution Approach 2:
The fluorinated and silicone-modified surface creates an inert biochemical environment that is resistant to fouling by biological materials. This inert surface property prevents blood components from adhering to the blood flow section, maintaining pump performance stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The surface modification leads to improved blood flow by reducing friction and thrombosis risk, while minimizing biofouling, thus enhancing the overall performance and safety of the blood pump.
Implementation Method 1
At least one external and/or internal surface of the blood flow section may include at least a portion of a surface modified by one or more fluorinated end groups and/or silicone end groups of an oligomer or copolymer
Implementation Method 2
At least one external and/or internal surface of the blood flow section may include at least a portion of a surface modified by one or more fluorinated end groups and/or silicone end groups of an oligomer or copolymer
Implementation Method 3
The surface modification may cause the surface to have a lower thrombogenicity compared to a thrombogenicity of the surface without the one or more fluorinated end groups and/or silicone end groups of an oligomer or copolymer
Implementation Method 4
The surface modification may cause the surface to have less biofouling compared to the biofouling of the surface without the one or more fluorinated end groups and/or silicone end groups of an oligomer or copolymer
Data Source
AI summary
A blood pump may be provided. The blood pump may include a blood flow section operably coupled to a distal end of a catheter. The blood flow section may be configured to cause blood to flow into a blood flow inlet of the blood flow section, through the blood flow section, and out of a blood flow outlet. At least one external and/or internal surface of the blood flow section may include at least a portion of a surface modified by one or more fluorinated end groups and/or silicone end groups of an oligomer or copolymer. The surface may be modified by one or more fluorinated end groups of an oligomer. The surface may be modified by one or more silicone end groups of a copolymer. The oligomer or copolymer may include a silicone, a polycarbonate, a polyurethane, a polyamide, a polyethylene, a polypropylene, a polysulfone, or a polyvinyl chloride.